滋养外胚层活检对冻融胚胎移植周期产科及围产结局的影响
该单中心回顾性队列研究纳入2013—2019年756例冻融囊胚移植后单胎活产患者,其中活检组241例、未活检组515例。控制协变量后,活检组妊娠期高血压疾病(HDP)风险显著升高(aOR 1.943,95%CI 1.072-3.521;P=0.029),前置胎盘、胎盘植入、胎儿生长受限及低出生体重比例无显著差异。
要点
- 冻融胚胎移植中,滋养外胚层活检可能增加妊娠期高血压疾病风险。
- 活检组与未活检组在前置胎盘、胎盘植入及胎儿生长受限上无显著差异。
- 低出生体重和极低出生体重比例在两组间无显著差异。
核心结论
- 滋养外胚层活检可能增加冻融胚胎移植周期中妊娠期高血压疾病的发生风险。
研究设计与样本
- 单中心大学附属生殖中心回顾性队列研究,纳入2013—2019年756例冻融囊胚移植后单胎活产患者,活检组241例、未活检组515例,年龄20—44岁。
主要发现
- 控制潜在协变量后,活检组发生HDP的概率显著高于未活检组(aOR 1.943,95%CI 1.072-3.521;P=0.029)。
- 两组在前置胎盘或胎盘植入概率上无显著差异。
- 两组胎儿生长受限率无显著差异(aOR 1.397;95%CI 0.815-2.395;P=0.224)。
- 两组低出生体重比例无显著差异(aOR 0.603;95%CI 0.336-1.084;P=0.091)。
- 两组极低出生体重比例无显著差异(aOR 2.948;95%CI 0.613-14.177;P=0.177)。
临床怎么用
- 对接受滋养外胚层活检后冻融胚胎移植的孕妇,应加强妊娠期高血压疾病的监测与预防。
局限性
- 本研究为单中心回顾性研究,可能限制研究结果的普适性。
- 作者建议开展前瞻性多中心随机试验以确认上述发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does trophectoderm biopsy for preimplantation genetic testing (PGT) increase the risk of obstetric or perinatal complications in frozen-thawed embryo transfer (FET) cycles? SUMMARY ANSWER: Trophectoderm biopsy may increase the risk of hypertensive disorders of pregnancy (HDP) in pregnancies following FET cycles. WHAT IS KNOWN ALREADY: Trophectoderm biopsy has replaced blastomere biopsy as the standard of care to procure cells for PGT analysis. Recently, there has been concern that trophectoderm biopsy may adversely impact obstetric and perinatal outcomes. Previous studies examining this question are limited by use of inappropriate control groups, small sample size or reporting on data that no longer reflects current IVF practice. STUDY DESIGN, SIZE, DURATION: This was a retrospective cohort study conducted at a single university-affiliated fertility center. A total of 756 patients who underwent FET with transfer of previously vitrified blastocysts that had either trophectoderm biopsy or were unbiopsied and resulted in a singleton live birth between 2013 and 2019 were included. PARTICIPANTS/MATERIALS, SETTING, METHODS: Obstetric and perinatal outcomes for patients aged 20-44 years who underwent FET with transfer of previously vitrified blastocysts that were either biopsied (n = 241) or unbiopsied (n = 515) were analyzed. Primary outcome was odds of placentation disorders including HDP and rate of fetal growth restriction (FGR). Binary logistic regression was performed to control for potential covariates. MAIN RESULTS AND THE ROLE OF CHANCE: The biopsy group was significantly older, had fewer anovulatory patients, was more often nulliparous and had fewer embryos transferred compared to the unbiopsied group. After controlling for potential covariates, the probability of developing HDP was significantly higher in the biopsy group compared with unbiopsied group (adjusted odds ratio (aOR) 1.943, 95% CI 1.072-3.521; P = 0.029).There was no significant difference between groups in the probability of placenta previa or placenta accreta. There was also no significant difference in the rate of FGR (aOR 1.397; 95% CI, 0.815-2.395; P = 0.224) or the proportion of low (aOR 0.603; 95% CI, 0.336-1.084; P = 0.091) or very low (aOR 2.948; 95% CI, 0.613-14.177; P = 0.177) birthweight infants comparing biopsied to unbiopsied groups. LIMITATIONS, REASON FOR CAUTION: This was a retrospective study performed at a single fertility center, which may limit the generalizability of our findings. WIDER IMPLICATIONS OF THE FINDINGS: Trophectoderm biopsy may increase the risk of HDP in FET cycles, however, a prospective multicenter randomized trial should be performed to confirm these findings. STUDY FUNDING/COMPETING INTEREST(S): No specific funding was obtained for this study. The authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: NA.
引用
- Makhijani R, Bartels CB, Godiwala P, et al. Impact of trophectoderm biopsy on obstetric and perinatal outcomes following frozen-thawed embryo transfer cycles. Hum Reprod. 2021. PMID: 33313768. doi:10.1093/humrep/deaa316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。